Overview

Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX

Status:
Completed

Trial end date:
2019-03-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multicentre, prospective phase II trial designed to evaluate the efficacy and safety of trastuzumab in combination with capecitabine and oxaliplatin as first-line therapy in patients with recurrent and/or metastatic HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction.

Phase:

Phase 2

Details

Lead Sponsor:

Asan Medical Center

Collaborator:

Hoffmann-La Roche

Treatments:

Capecitabine
Oxaliplatin
Trastuzumab